163 search results for: type 2 inflammation
ADVENT in Orlando, 2025
Type 2 inflammation contributes to many dermatologic diseases, which may lead to potentially life-changing burdens and challenges to patients and caregivers. By uncovering the role of type 2 inflammation in the pathophysiology of AD, PN, CSU, and BP, we can move forward in our understanding of each disease. Join global experts for an educational symposium on March 8th that will uncover the role of type 2 inflammation in the pathophysiology of AD, PN, CSU, and BP and explore questions driving current research in each disease.
Prurigo Nodularis (PN): Understanding Its Clinical Features, Complex Burden, and Underlying Mechanisms
Explore the clinical features, complex burden, and underlying mechanisms of PN.
COPD and Asthma: What's the Difference and Is There a Link?
Explore the characteristics of COPD and asthma, focusing on their shared inflammatory mechanisms and key clinical differences.
Factors Contributing to Diagnostic Delays in Bullous Pemphigoid
Dr. Donna Culton focuses on the challenges of diagnosis and the unmet needs for patients with BP
Unmet Needs for Bullous Pemphigoid (BP): Limitations of Diagnosis and Conventional Therapies
In this ADVENT symposium at the 2024 EADV meeting, Dr. Donna Culton focuses on the challenges of diagnosis and the unmet needs for patients with BP.
New Horizons: The Emergence of Targeted Therapies
In this ADVENT symposium at the 2024 EADV meeting, Professor Dedee Murrell reviews the current treatment guidelines for bullous pemphigoid (BP) and the emergence of targeted therapies including a highlight of the LIBERTY-BP ADEPT interim results.
The Weight of Breath: The Impact of Pediatric Asthma on Patients and Caregivers
Learn about the multifaceted burden of uncontrolled pediatric asthma on patients and their caregivers.
Etiology and Diagnosis of Bullous Pemphigoid
Professor Joost Meijer discusses the complex etiology and diagnosis of BP
Bullous Pemphigoid (BP): Don't Miss the Diagnosis
This static infographic covers the clinical presentations, diagnostic challenges, and disease burden of bullous pemphigoid (BP), a chronic relapsing autoimmune skin disease. Review the steps of diagnosis, which include clinical assessment and laboratory work. Explore comorbidities associated with BP and how they impact patient quality of life.
ADVENT at WCI 2025
Join ADVENT for an educational symposium on PN at WCI 2025!
Current systemic therapies have been shown to induce remission in a subset of AD patients
Dr. Ramien discusses evidence suggesting early targeted inhibition in pediatric patients may prevent disease progression or lead to remission.
Can targeting IL-4 and IL-13 have an effect on relieving the burden of atopic and non-atopic comorbidities in AD?
Dr. Amy Paller discusses how targeting IL-4 and IL-13 can improve burden of AD.
